Ibritumomab Tiuxetan

Ibritumomab tiuxetan (ZevalinĀ®, Biogen IDEC, San Diego, CA, USA) is a murine anti-CD20 antibody from which rituximab, a humanized antibody, was engineered. Zevalin was derived from ibritumomab by binding with tiuxetan, which chelates the radionuclide 90Yttrium through carboxyl groups. 90Yttrium-ibritumomab tiuxetan can selectively deliver therapeutic radiation dose to CD20 antigen expressing tumors, and can prevent significant radiation exposure to normal tissues overlying the tumor mass (37,38).

Zevalin has been approved by the U.S. FDA for radioimmunotherapy in B-cell lymphoma (39). The activity of ibritumomab tiuxetan had been evaluated or is under investigation for rituximab-refractory lymphoma patients, relapsed diffuse large B-cell or mantle cell lymphoma patients, or as a part of high-dose chemotherapy with autologous hematopoietic stem cell support (40). The results of phase I, II, and randomized trials showed that the single doses of Zevalin are safe and effective in the treatment of patients with relapsed B-cell NHL with a response rate of 60%-80% (40). Unfortunately, no data are available regarding the impact of polymorphisms on the clinical outcomes after Zevalin therapy.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment